POWERFUL NEWS:

MMRF PRESS RELEASES


Multiple Myeloma Research Foundation (MMRF) Saddened by Loss of Dear Friend and Former Board Member Bob DeBaun


Norwalk, Conn. — December 30, 2010

The Multiple Myeloma Research Foundation (MMRF) mourns the loss of dear friend and former Board Member Robert (Bob) DeBaun, who, on December 29, 2010, died of multiple myeloma, an incurable blood cancer. DeBaun had been living with the disease since 2002.

“Bob DeBaun was an amazing man who deeply touched the lives of all those who had the privilege of knowing him. He will be greatly missed but never forgotten for his kindness, his thoughtful guidance, and, above all, his friendship. Our thoughts and prayers are with his wife, Jane, and family and friends during this very sad time,” said Kathy Giusti, Founder and CEO of the Multiple Myeloma Research Foundation, and a multiple myeloma patient.

DeBaun previously served on the MMRF and MMRC Board of Directors. In addition to his strong and visionary governance, DeBaun took a leadership role at both the MMRF Chicago Awards Dinner and MMRF Race for Research-Chicago to raise critical research funds. In 2009, he was the recipient of the MMRF Spirit of Hope Award at the Chicago Awards Dinner.

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)
Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $150 million since its inception to fund nearly 120 laboratories worldwide, including 40 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 27 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org